Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Targeted funding strategies and policy interventions are key to make rare disease treatments…
Coinciding with the recent observance of Rare Diseases Day on February 29, 2024, Anil Matai, Director General of OPPI, accentuated…
Lab Weighing: Achieve Compliance with Ease
Matching the ever-demanding regulatory needs of the pharmaceutical industry can be challenging. You can take a productive step…
Express Pharma March 2024
India's Foremost Pharma & Biotech Magazine ~ Championing Innovation, Powering Progress
Allecra’s EXBLIFEP approval to treat cUTIs provides valuable new weapon to tackle ESBL mediated AMR:…
In addition to the FDA approval, EXBLIFEP has also been submitted for marketing approval in the EU and received a positive opinion…
Biocon Biologics gets US market entry date for Bmab 1200, a proposed biosimilar to Stelara
Stelara (Ustekinumab) has been approved for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and…
Suven, Cohance announce merger
The merged platform to comprise three distinct business units – Pharma CDMO, Spec Chem CDMO, and API+ (inclusive of formulations)
Nezglyal remains promising therapy despite EMA’s market authorisation refusal: GlobalData
Nezglyal is a novel orally bioavailable and selective peroxisome proliferator-activated receptor (PPAR) gamma agonist that is…
Innovations paving the way for drug discovery of rare diseases
Sanjay Vyas, Executive VP and MD, Parexel examines the challenges associated with rare diseases in India, and emphasises on the…
FDA denial could delay launch of Minerva’s schizophrenia treatment roluperidone by at least two…
To address the clinical deficiencies stated in the CRL, Minerva must provide additional safety and efficacy data for roluperidone…
We have attempted to make the dengue vaccine more affordable than other innovative vaccines
Gary Dubin, President, Global Vaccine Business Unit, Takeda, and Dion Warren, Head of Multi-Country Organization, India &…